This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The new “pathoblocker” treatment aims to disarm pathogens and suppress the disease-causing properties of P.
DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.
Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning. Along with this, the high quality DNA clones and gene clones are customized as per the need and requirement. Genetic Synthesis: It includes in-vitro synthesis of any DNA sequence or gene without the involvement of initial template.
Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. CARB-X will provide Polyphor with initial funding of up to $2.62 million to complete the hit-to-lead stage and up to USD 15.82 million if certain project milestones are met.
Transformation / Transfection: The expression vector is introduced into the host organism (bacterial, yeast, insect, algal, cell-free or mammalian cells) through transformation (for bacteria and yeast) or transfection (for mammalian cells).
The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content